Optus Pharmaceutical applies for Korean MFDS approval for presbyopia treatment 'Clothy'
Predicted impact: Low
Presbyterian drug approval filing already reported; commercialization is targeted for 2028
Optus Pharmaceutical옵투스제약
131030 · KOSDAQ · ₩131030 · 옵투스제약
₩5,950▲ ₩100 (1.71%)End-of-day · Oct 28, 2026 · End-of-day prices.
Optus Pharmaceutical files for approval of 'Clossi', a presbyopia drug, targeting commercialization in 2028
Predicted impact: Low
Drug approval filing with commercialization targeted for 2028; small company and distant timeline.
Also known as: Optus Pharmaceutical / 옵투스제약 / 131030 / KRX:131030
Source: KRX statistical information